Gordillo ARJ, Ávila CMC

Idioma: Español
Referencias bibliográficas: 31
Paginas: 137-143
Archivo PDF: 518.84 Kb.

RESUMEN

Se conoce que las mutaciones de la secuencia de los aminoácidos y de la apolipoproteína-E se expresan en la clínica como síndrome nefrótico, esta nueva entidad se ha llamado nefropatía por lipoproteína-E (NLE), la que cursa con dislipidemia severa (tipo III), edema crónico generalizado y proteinuria masiva; se trata de una enfermedad renal progresiva que conduce a los pacientes a una insuficiencia renal crónica que no responde a la terapia médica habitual; el escaso reconocimiento de esta entidad o bien debido a un diagnóstico errado hace que el médico indique al paciente medicamentos que ordinariamente emplea para el síndrome nefrótico: los corticosteroides o la ciclosporina-A, lo que agrava la dislipidemia y consecuentemente el síndrome nefrótico, ya que propicia la hipertensión arterial en los pacientes, sin obtener una respuesta terapéutica. Es así como en esta ocasión se reporta el caso de una niña con las manifestaciones de un síndrome nefrótico común, excepto por la presencia de dislipidemia tipo III (severa), con nula respuesta al tratamiento convencional, pero con buena respuesta a la dieta y a la terapia intensiva.

REFERENCIAS (EN ESTE ARTÍCULO)

1. International Study of Kidney Disease in Children. Nephrotic syndrome in children: Prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. Kidney Internat 1978; 13(2): 159-165.

2. Hatters D, Peters-Libeau CA, Weisgraber K. Apolipoprotein E structure: insights into function. Trends Biochem Sci 2006; 31(8): 444-454.

3. Liberopoulos E, Siamopolous K, Elisaf M. Apolipoprotein E and renal disease. Am J Kidney Dis 2004; 43(2): 223-233.

4. Saito T, Sato H, Kudo K, Oikawa S, Shibata T, Hara Y et al. Lipoprotein glomerulopathy. Glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. Am J Kidney Dis 1989; 13(2): 148-153.

5. Demetrius E, Orchard T, Lombardozzi Yunis EJ, McCauley J, Agostini R, Diamond R. Atypical hyperlipidemia and nephropathy associated with apolipoprotein-E homozygosity. J Am Soc Nephrol 1995; 6(4): 1170-1177.

6. Ramin S, Wu H, Yue L, Mazzone T, Shwartz M, Arruda JA et al. Lipoprotein glomerulopathy: a new apolipoprotein mutation with enhanced glomerular binding. Am J Kidney Dis 2006; 47(3): 539-548.

7. Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis 2006; 47(2): 199-211.

8. Chang Ch, Lin Ch, Chen JY, Yang AH, Shiao MS, Kao JT et al. Lipoprotein glomerulopathy associated with psoriasis vulgaris: Report of 2 cases with apolipoprotein E3/E3. Am J Kid Dis 2003; 42(3): E14-23.

9. McCrindle BW, Urbina EM, Dennison BH, Jacobson MS, Steinberg J, Rochini A et al. Drug therapy of high-risk lipid abnormalities in children and adolescents. Circulation 2007; 115(14): 1948-1967.

10. Newman WP 3rd, Freedman DS, Voors AW, Gard PD, Srinivasan SR, Cresanta JL et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. N Engl J Med 1986; 314(3): 138-144.

11. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy R, Watigney W. For the bogalusa heart study: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults; The Bogalusa Heart Study. N Engl J Med 1998; 338(23): 1650-1656.

12. Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking: a preliminary report from the pathobiological determinants of atherosclerosis in youth (PDAY) research group. JAMA 1990; 264(23): 3018-3024.

13. Appel GB. Lipid abnormalities in renal diseases. Kidney Int 1991; 39(1): 184-183.

14. Saito T. Abnormal lipid metabolism and renal disorders. Tohoku J Exp Med 1997; 181(3): 321-337.

15. Hansson G, Robertson A, Söderberg C. Inflammation and atherosclerosis. Annu Rev Pathol Mech Dis 2006; 1: 297-329.

16. US Preventive services task force: Screening for lipid disorders in children: US preventive services task force. Pediatrics 2007: e215-219.

17. Ieri N, Hotta O, Taguma Y. Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. Am J Kidney Dis 2003; 41(1): 244-249.

18. Arai T, Yamashita S, Yamane M, Manabe N, Matsuzaki T, Kiriyama K et al. Disappearance of intraglomerular thrombi and marked improvement of nephritic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. Atherosclerosis 2003; 169(2): 293-299.

19. Zhang P, Matalon R, Kaplan L, Kumar A, Gallo G. Lipoprotein glomerulopathy, first report in a Chinese male. Am J Kidney Dis 1994; 24(6): 942-950.

20. Abrass C. Celular lipid metabolism and the role of lipids in progressive renal disease. Am J Kidney Dis 2004; 24: 46-53.

21. Cholesterol in childhood. American Academy of Pediatrics. Committee on Nutrition. Pediatrics 1998; 101(1): 141-147.

22. Haney E, Huffman LK, Bougatsos C, Freeman M, Seiner R, Nelson H. Screening and treatment for lipid disorders in children and adolescents: Systematic evidence review for the US preventive services task force. Pediatrics 2007; 120(1): e189-e200.

23. de Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Rusell L, Perron SP et al. Efficacy and safety of simvastatin therapy in children with familial hypercholesterolemia study group. Circulation 2002; 106(17): 2231-2237.

24. McCridle B, Ose L, Marais A. Efficacy and safety of atorvastatin in children and adolescents with familiar hypercholesterolemia or severe hyperlipidemia, a multicenter randomized, placebo control trial. J Pediatr 2003; 143(1): 74-80.

25. Dacobu J, Brasseur D, Chaudron JM, Deslypere JP, Muls E, Thomson M. Simvastatin in Children. Lancet 1992; 339(8807): 1488.

26. Hedman M, Matikainen T, Föhr A, Lappi M, Piippo S, Muutinen et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familiar hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab 2005; 90(4): 142-152.

27. Machida SI, Inaba A, Harada T, Aihana Y, Yokota Sh. Amelioration of steroids and cyclosporineresistant Nephrotic syndrome by pravastatin. Pediat Nephrol 2007; 22(4): 603-606.

28. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007; 82(11): 1381-1390.

29. Steffens S, Mach Francois. Drug insight: immunomodulatory effects of statins-potential benefits for renal patients? Nature Clin Prac Nephrol 2006; 2(7): 378-387.

30. Wheeler KA, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolemia. Arch Dis Child 1985; 60(1): 34-37.

31. Superko R, Chronos N. Hypercholesterolemia and dyslipidemia: Issues for the clinician. Current Treat Opt Cardiovas Med 2003; 5(1): 35-50.